Venus Remedies Crecimiento futuro

Future controles de criterios 0/6

Actualmente no disponemos de suficiente cobertura de analistas para prever el crecimiento y los ingresos de Venus Remedies.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	17.9%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	None
Última actualización	n/a

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

Shareholders May Not Be So Generous With Venus Remedies Limited's (NSE:VENUSREM) CEO Compensation And Here's Why

Sep 17

Venus Remedies Limited (NSE:VENUSREM) Held Back By Insufficient Growth Even After Shares Climb 26%

Jun 14

Venus Remedies (NSE:VENUSREM) Could Easily Take On More Debt

Jun 13

Venus Remedies Limited (NSE:VENUSREM) Not Doing Enough For Some Investors As Its Shares Slump 26%

Mar 14

I Ran A Stock Scan For Earnings Growth And Venus Remedies (NSE:VENUSREM) Passed With Ease

Mar 30

Why Investors Shouldn't Be Surprised By Venus Remedies Limited's (NSE:VENUSREM) 25% Share Price Plunge

Feb 24

Is Venus Remedies (NSE:VENUSREM) Using Too Much Debt?

Feb 01

Here's Why We Think Venus Remedies (NSE:VENUSREM) Is Well Worth Watching

Nov 16

Venus Remedies Limited's (NSE:VENUSREM) Stock Is Going Strong: Have Financials A Role To Play?

Mar 11

We Think Venus Remedies (NSE:VENUSREM) Is Taking Some Risk With Its Debt

Jan 14

Does Venus Remedies's (NSE:VENUSREM) Statutory Profit Adequately Reflect Its Underlying Profit?

Nov 23

Is Venus Remedies (NSE:VENUSREM) A Risky Investment?

Sep 22

En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como Venus Remedies no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.

Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.

Previsiones de crecimiento de beneficios e ingresos

NSEI:VENUSREM - Estimaciones futuras de los analistas y datos financieros pasados (INR Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
9/30/2024	6,146	221	442	653	N/A
6/30/2024	6,149	285	N/A	N/A	N/A
3/31/2024	6,014	285	238	373	N/A
12/31/2023	5,619	290	N/A	N/A	N/A
9/30/2023	5,354	255	67	150	N/A
6/30/2023	5,076	209	N/A	N/A	N/A
3/31/2023	5,555	266	288	366	N/A
12/31/2022	5,418	157	N/A	N/A	N/A
9/30/2022	5,492	181	230	329	N/A
6/30/2022	6,119	359	N/A	N/A	N/A
3/31/2022	6,002	407	274	411	N/A
12/31/2021	5,702	756	N/A	N/A	N/A
9/30/2021	5,684	816	809	681	N/A
6/30/2021	5,087	715	N/A	N/A	N/A
3/31/2021	5,481	618	1,241	1,318	N/A
12/31/2020	5,320	213	N/A	N/A	N/A
9/30/2020	4,939	87	1,156	1,196	N/A
6/30/2020	4,586	-40	N/A	N/A	N/A
3/31/2020	3,407	-100	698	776	N/A
12/31/2019	3,490	-161	N/A	N/A	N/A
9/30/2019	3,281	-269	506	596	N/A
6/30/2019	3,286	-269	N/A	N/A	N/A
3/31/2019	3,219	-286	354	453	N/A
3/31/2018	3,724	-307	N/A	312	N/A
3/31/2017	4,000	-171	N/A	589	N/A
3/31/2016	4,183	17	N/A	469	N/A
3/31/2015	4,640	52	N/A	678	N/A
3/31/2014	5,416	643	N/A	526	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de VENUSREM es superior a la tasa de ahorro (6.7%).

Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de VENUSREM crezcan más rápidamente que el mercado Indian

Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de VENUSREM crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de VENUSREM crezcan más rápidamente que el mercado de Indian.

Ingresos de alto crecimiento: No hay datos suficientes para determinar si se prevé que los ingresos de VENUSREM crezcan a un ritmo superior a 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de VENUSREM se prevé que sea elevada dentro de 3 años.

Venus Remedies Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Second quarter 2025 earnings released: EPS: ₹2.63 (vs ₹7.44 in 2Q 2024)

Now 22% undervalued after recent price drop

Venus Remedies Limited to Report First Half, 2025 Results on Oct 29, 2024

Now 22% undervalued after recent price drop

Venus Remedies Limited Announces Executive Appointments

Shareholders May Not Be So Generous With Venus Remedies Limited's (NSE:VENUSREM) CEO Compensation And Here's Why

Venus Remedies Limited to Report Q2, 2025 Results on Nov 14, 2024

Venus Remedies Limited, Annual General Meeting, Sep 23, 2024

First quarter 2025 earnings released: EPS: ₹0.92 (vs ₹0.88 in 1Q 2024)

Venus Remedies Limited to Report Q1, 2025 Results on Aug 13, 2024

Now 24% overvalued after recent price rise

Now 21% overvalued after recent price rise

Now 21% overvalued after recent price rise

Venus Remedies Limited (NSE:VENUSREM) Held Back By Insufficient Growth Even After Shares Climb 26%

Now 27% overvalued after recent price rise

Venus Remedies (NSE:VENUSREM) Could Easily Take On More Debt

Investor sentiment improves as stock rises 17%

Full year 2024 earnings released: EPS: ₹21.31 (vs ₹19.87 in FY 2023)

Venus Remedies Limited to Report Q4, 2024 Results on May 30, 2024

Investor sentiment improves as stock rises 16%

Venus Remedies Limited (NSE:VENUSREM) Not Doing Enough For Some Investors As Its Shares Slump 26%

Third quarter 2024 earnings released: EPS: ₹5.13 (vs ₹2.46 in 3Q 2023)

Venus Remedies Limited to Report Q3, 2024 Results on Feb 14, 2024

Second quarter 2024 earnings released: EPS: ₹7.44 (vs ₹3.99 in 2Q 2023)

Investor sentiment improves as stock rises 23%

Calculating The Fair Value Of Venus Remedies Limited (NSE:VENUSREM)

Venus Remedies Limited to Report Q2, 2024 Results on Nov 09, 2023

New minor risk - Share price stability

Investor sentiment improves as stock rises 19%

Now 20% undervalued after recent price drop

Venus Remedies Limited Receives Marketing Approval from the Philippines for Six Key Chemotherapy Drugs

Investor sentiment deteriorates as stock falls 15%

New minor risk - Profit margin trend

Venus Remedies Limited to Report Q1, 2024 Results on Aug 14, 2023

Full year 2023 earnings released: EPS: ₹19.87 (vs ₹30.86 in FY 2022)

Venus Remedies Limited, Annual General Meeting, Aug 24, 2023

Investor sentiment improves as stock rises 15%

Venus Remedies Limited Receives Ukrainian GMP Approval for Its Carbapenem, Oncology Parenteral Facilities

Venus Remedies (NSE:VENUSREM) Seems To Use Debt Rather Sparingly

Full year 2023 earnings released: EPS: ₹19.88 (vs ₹30.86 in FY 2022)

Investor sentiment improves as stock rises 18%

Investor sentiment improves as stock rises 20%

Less than half of directors are independent

Third quarter 2023 earnings released: EPS: ₹2.46 (vs ₹4.22 in 3Q 2022)

Second quarter 2023 earnings released: EPS: ₹3.99 (vs ₹17.32 in 2Q 2022)

First quarter 2023 earnings released: EPS: ₹5.16 (vs ₹8.86 in 1Q 2022)

Venus Remedies Limited to Report Q2, 2023 Results on Nov 14, 2022

Venus Remedies Limited, Annual General Meeting, Aug 23, 2022

Venus Remedies Limited to Report Q1, 2023 Results on Jul 30, 2022

Now 21% undervalued after recent price drop

Estimating The Fair Value Of Venus Remedies Limited (NSE:VENUSREM)

Now 25% undervalued after recent price drop

Chairman recently bought ₹28m worth of stock

Is Venus Remedies (NSE:VENUSREM) Using Too Much Debt?

Now 19% undervalued after recent price drop

Full year 2022 earnings released: EPS: ₹30.86 (vs ₹50.05 in FY 2021)

Venus Remedies Limited Appoints Akshansh Chaudhary as Additional Director (Whole Time Director)

Investor sentiment improved over the past week

Venus Remedies Limited to Report Q4, 2022 Results on May 27, 2022

Investor sentiment improved over the past week

I Ran A Stock Scan For Earnings Growth And Venus Remedies (NSE:VENUSREM) Passed With Ease

Why Investors Shouldn't Be Surprised By Venus Remedies Limited's (NSE:VENUSREM) 25% Share Price Plunge

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Is Venus Remedies (NSE:VENUSREM) Using Too Much Debt?

Investor sentiment deteriorated over the past week

Here's Why We Think Venus Remedies (NSE:VENUSREM) Is Well Worth Watching

Second quarter 2022 earnings released: EPS ₹17.32 (vs ₹10.55 in 2Q 2021)

Investor sentiment improved over the past week

First quarter 2022 earnings released: EPS ₹8.86 (vs ₹6.08 in 1Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS ₹50.04 (vs ₹8.10 loss in FY 2020)

Venus Remedies Limited announced that it has received INR 137.52425 million in funding

Investor sentiment improved over the past week

Investor sentiment improved over the past week